Evidence Synthesis
CONCORDBIO's 64.56% represents a significant acceleration from its 24.96% quarterly reading, indicating a substantial improvement in the company's gross margin.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 16 Sept 2026, 00:28
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
CONCORDBIO's 64.56% represents a significant acceleration from its 24.96% quarterly reading, indicating a substantial improvement in the company's gross margin.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 64.56 % | 24.96 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 24.96 % | 24.84 | ▲ |
| REVENUE_GROWTH_YOY | 26.2 % | 31.1 | ▼ |
| EPS_ACTUAL | 6.03 INR | 6.308 | ▼ |
| EPS_SURPRISE_PERCENT | 0.256 % | -0.111 | ▲ |
| PRICE_CHANGE_PERCENT | -2.172 % | — | - |
| DAILY_VOLUME | 97,030 shares | 1,62,300 | ▼ |
| CLOSE_PRICE | 1,473 INR | 1,505.7 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.8 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 2 count | 2 | - |
| TARGET_PRICE_PREMIUM | 5.27 % | — | - |